| 0.19 -0.005 (-2.46%) | 04-24 15:16 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 6.93 |
1-year : | 7.69 |
| Resists | First : | 5.93 |
Second : | 6.59 |
| Pivot price | 5.44 |
|||
| Supports | First : | 4.88 |
Second : | 4.06 |
| MAs | MA(5) : | 5.08 |
MA(20) : | 5.56 |
| MA(100) : | 4.72  |
MA(250) : | 6.39 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 7.5 |
D(3) : | 8.8 |
| RSI | RSI(14): 38.1 |
|||
| 52-week | High : | 11.89 | Low : | 2.38 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ PCT ] has closed above bottom band by 15.2%. Bollinger Bands are 21.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 5.31 - 5.35 | 5.35 - 5.38 |
| Low: | 4.88 - 4.92 | 4.92 - 4.95 |
| Close: | 5.04 - 5.1 | 5.1 - 5.15 |
Provectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes. It develops PV-10, an investigational autolytic cancer immunotherapy for adult solid tumor cancers, such as melanoma and gastrointestinal tumors, including hepatocellular carcinoma; colorectal cancer metastatic to the liver; neuroendocrine tumors metastatic to the liver; uveal melanoma metastatic to the liver; and pediatric solid tumor cancers, such as neuroblastoma, Ewing sarcoma, rhabdomyosarcoma, and osteosarcoma. The company is also developing oral formulations of current good manufacturing practice rose bengal sodium (cGMP RBS) for the treatment of adult solid tumor cancers, such as head and neck, breast, testicular, and colorectal cancers; pediatric blood cancers, including leukemia; coronavirus, an acute respiratory syndrome; multi-drug resistant bacteria, such as gram-negative bacteria; and for eye diseases, including infectious keratitis. In addition, it develops PH-10, an investigational immuno-dermatology agent for the treatment of inflammatory dermatoses, such as psoriasis and atopic dermatitis. The company was formerly known as Provectus Pharmaceuticals, Inc. and changed its name to Provectus Biopharmaceuticals, Inc. in December 2013. Provectus Biopharmaceuticals, Inc. was incorporated in 2002 and is based in Knoxville, Tennessee.
Thu, 18 Apr 2024
Provectus Biopharmaceuticals Announces Publication of Preclinical Data of Oral Administration of Provectus Rose ... - GlobeNewswire
Tue, 16 Apr 2024
Provectus Pharmaceuticals Announces New Leadership and Strategy - TipRanks.com - TipRanks
Tue, 16 Apr 2024
Provectus Biopharmaceuticals Announces Management Additions and Reiterates Commitment to Shareholder Value ... - GlobeNewswire
Thu, 11 Apr 2024
Provectus Biopharmaceuticals Announces Presentation of Cancer Immunotherapy PV-10 Poster for HNSCC at AACR ... - GlobeNewswire
Wed, 27 Mar 2024
Provectus Pharmaceuticals Strikes Key Ophthalmology Therapy Deal - TipRanks.com - TipRanks
Tue, 26 Mar 2024
Provectus Pharmaceuticals Executives Transition and Compensation Details - TipRanks.com - TipRanks
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
PNK
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 164 (M) |
| Shares Float | 89 (M) |
| Held by Insiders | 14.3 (%) |
| Held by Institutions | 61.3 (%) |
| Shares Short | 37,880 (K) |
| Shares Short P.Month | 37,210 (K) |
| EPS | -0.63 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.55 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -7.5 % |
| Return on Equity (ttm) | -21.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.6 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -95 (M) |
| Levered Free Cash Flow | -169 (M) |
| PE Ratio | -7.88 |
| PEG Ratio | 0 |
| Price to Book value | 1.93 |
| Price to Sales | 0 |
| Price to Cash Flow | -8.6 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|